HRS-5632
HRS-5632 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Nov 2, 2026: “Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human Study”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on HRS-5632
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%.”
- 1 lab in 1 country
- 1 of 1 finding with company ties
- Human trial1
Studies in people
1 study gave HRS-5632 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases lipoprotein≥90% reduction at ≥10 mg; at week 48, ≥90% reduction in 87.5% and 100.0% of the 200 mg and 400 mg cohorts, respectively | Randomized trialapproximately one year at 200 mg or 400 mg | 40 people18 to 55 yearsMidlife adults; Healthy participants with lipoprotein(a) ≥75 nmol/L | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
What did studies of HRS-5632 find?
1Studies of HRS-5632 measured one outcome, lipoprotein.
Lipoprotein
downin humans1
1 study
Lipoprotein
downin humans1
HRS-5632 decreases lipoprotein in humans (Healthy participants with lipoprotein(a) ≥75 nmol/L) (≥90% reduction at ≥10 mg; at week 48, ≥90% reduction in 87.5% and 100.0% of the 200 mg and 400 mg cohorts, respectively).
“HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%.”
Human trialHealthy participants with lipoprotein(a) ≥75 nmol/L10 mg or higherapproximately one year at 200 mg or 400 mgn = 40
AHA Scientific Sessions 2026 abstract